Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million ...

In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

Misinformation is becoming more prevalent with the rise of unregulated social media content. Combatting this and helping men ...

The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...

Weber said it is the right time to appoint a successor, given the company's "competitive growth outlook, new product launches ...